Majd Issa, MD - 0101278655 - Academic Appointments, Publications

	Majd Issa, MD	LICENSE # 0101278655

		Issue Date: 4/27/2023 Expiration Date: 8/31/2024 Status: Current Active

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Academic Appointments

Last Updated 6/12/2023

Oakland University William Beaumont School of Medicine Rochester, MI
Rank: Assistant Professor
Years: 2014-2018

Ohio State University College Of Medicine And Public Health - Columbus OH
Rank: Assistant Professor
Years: 2018-2020

Academic Appointments - Non-US

Last Updated 6/12/2023

None Reported

Publications

(up to ten in the last five years)

Last Updated 6/12/2023

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
J Immunother Cancer.
Date: 03 2020
10.1136/jitc-2020-000538

A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors
Oral Oncol.
110:104900
Date: 11 2020
www.sciencedirect.com/science/article/pii/S1368837520303365?via%3Dihub

Treatment Outcomes of Head and Neck Cancer Patients in the Elderly Receiving Different Chemoradiation Combinations: A Single-Center Experience
Oncol Res Treat.
44(10):521-529
Date: 08 2021
doi.org/10.1159/000518548

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
Mol Clin Oncol.
15(5):240
Date: 09 2021

Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort
BMC Cancer
22(1):767.
Date: 07 2022
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-09809-5

Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.
Expert Rev Anticancer Ther.
22(8):861-874.
Date: 08 2022
doi.org/10.1080/14737140.2022.2094772